The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwAL 2026 | Expanding donor access for allogeneic transplantation in AML
Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil, FMedSci, University of Birmingham, Birmingham, UK, discusses advances in donor selection that could improve equitable access to allogeneic stem cell transplantation for patients acute myeloid leukemia (AML) from ethnic minority backgrounds. He highlights evidence from the Phase II ACCESS trial (NCT04904588) supporting the use of mismatched unrelated donors with post-transplant cyclophosphamide, which could expand donor availability and reduce disparities in access to transplantation. This interview took place at the 8th International Workshop on Acute Leukemias (iwAL 2026), held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
